Clinical trialRSS3 days ago
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
WHY IT MATTERSIf you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
Clinical trialUNITERAREApr 3
Researchers at the University of Alabama at Birmingham are looking for premature babies to join a study about pulmonary hypertension—a condition where blood pressure in the lungs gets too high. The study will test different oxygen level targets to see which approach helps prevent or reduce lung problems in preterm infants. This trial is now actively recruiting participants and is expected to start in April 2026.
WHY IT MATTERSThis trial directly addresses a common complication in premature infants where improper oxygen management can cause lasting lung damage, making oxygen saturation targeting strategies critical for improving long-term outcomes in this vulnerable population.
Clinical trialCLINICALTRIALSMar 26
Doctors are building a national database to collect information from 500 patients with pulmonary alveolar proteinosis (PAP), a rare lung disease. This registry will help researchers better understand PAP, improve how doctors diagnose it, and test new treatments. Patients who join will have a voice in deciding what research gets done.
WHY IT MATTERSThis is an active recruitment opportunity for PAP patients to directly influence research priorities and gain access to new diagnostic tests and experimental therapies being evaluated through the registry.